Juvion Life Sciences

AI Quick Summary

Juvion Life Sciences develops therapeutics to prevent age-related decline in mobility and delay the onset of sarcopenia by stabilizing neuromuscular junctions (NMJs), which connect neurons and muscles. Executive summaryOverview: Over the past century, while lifespan has increased significantly, healthspan has not kept pace, leaving nearly 33-50% of individuals over 65 with reduced mobility and declining health. Conditions like sarcopenia—a progressive disorder characterized by age-related loss of muscle strength and mass—become increasingly common with age, affecting nearly 50% among those over 80. These issues significantly increase the risks of falls, hospitalizations, social isolation, and a diminished quality of life, often due to the degeneration of motor function, which connects neurons and muscles. Despite over $100 billion being spent annually on healthcare costs related to decline in mobility and Sarcopenia in the U.S. alone, this challenge remains largely unaddressed. With one in six people expected to be over the age of 60 by 2030, these concerns represent a growing societal problem.Juvion Life Sciences, an EPFL spin-off, is founded on pioneered research over the past decade that identifies the crucial roles of two proteins, Trio and Complexin, in preserving motor function. To our knowledge, we are the first to show that reactivating these mechanisms can greatly mitigate mobility loss associated with aging. These scientific discoveries have been highlighted in multiple outlets, including The Scientist magazine.Juvion is transforming these groundbreaking scientific discoveries into next-generation therapeutic solutions derived from natural resources to support healthier aging. These solutions aim to be accessible to individuals across various age groups, helping to preserve motor function over a longer period as they age. The development of these compounds is supported by a cutting-edge proprietary in vivo platform that integrates AI, robotics, and machine learning, enabling a sustainable, faster, and more cost-effective approach using Drosophila as a primary predictive animal model. JUV-083, one of Juvion’s leading candidates, is currently undergoing validation in mouse models and is on track to advance to human testing. With a profound understanding of age-related motor function decline and the development of its innovative platform, Juvion is well-positioned to deliver cutting-edge solutions to the rapidly expanding health and wellness market. By promoting healthier aging and delaying conditions like sarcopenia, Juvion aims to narrow the gap between life span and healthspan for millions of people. Go-to-Market Strategy /Traction/Business plan: With the rapidly growing aging population, the market for anti-aging products is expanding at an unprecedented rate. Additionally, the global dietary supplement market is projected to reach $221 billion by 2030, with an expected CAGR of 6.5% from 2024 to 2030. According to McKinsey Health Institute, extending healthspan by just one year could create an astonishing $38 trillion in societal value in the U.S. alone. To align with this rapidly growing market, Juvion has two product portfolios as part of its addressable market strategy.Juvion Therapeutic Solutions: Juvion's product will be the first scientifically backed preventative solution to address age-related mobility decline and delay sarcopenia by maintaining neuron-muscle connectivity as aging progresses. The product is expected to be market-ready by 2027, following successful six-month clinical evidence tests in humans. Distribution will follow a B2B strategy, and we are already in discussions with DSM-Firmenich, Mitsubishi Life Sciences (Japan), and Cipla (India) to establish global partnerships.Juvion Platform: Juvion’s proprietary platform is set to begin generating revenue starting in 2025. The platform is designed to test compounds for efficacy in improving motor function and mobility, supporting scientific licensing agreements. An agreement has already been signed with DSM-firmenich to test their compounds, and active discussions are ongoing with Nestlé for similar collaborations. IP: In 2022, the discovery of the Trio protein's role in maintaining neuron-muscle connectivity was submitted for IP protection through EPFL's TTO office. Potential leads, including JUV-083, are being finalized for IP protection, which also covers compound combinations to enhance effectiveness under the same framework. Furthermore, new technology within the Juvion platform is being prepared for future patent applications. Securing IP for both Juvion's products and platform will provide a crucial competitive edge, safeguarding proprietary formulations as we progress toward product development and market launch.

Project Idea Metadata

Project Idea Name: Juvion Life Sciences
Date: 9/5/2024 12:23:57 PM
Administrators:
- Soumya Banerjee

Project Idea Description

Executive summary

Overview:

Over the past century, while lifespan has increased significantly, healthspan has not kept pace, leaving nearly 33-50% of individuals over 65 with reduced mobility and declining health. Conditions like sarcopenia—a progressive disorder characterized by age-related loss of muscle strength and mass—become increasingly common with age, affecting nearly 50% among those over 80. These issues significantly increase the risks of falls, hospitalizations, social isolation, and a diminished quality of life, often due to the degeneration of motor function, which connects neurons and muscles. Despite over $100 billion being spent annually on healthcare costs related to decline in mobility and Sarcopenia in the U.S. alone, this challenge remains largely unaddressed. With one in six people expected to be over the age of 60 by 2030, these concerns represent a growing societal problem.

Juvion Life Sciences, an EPFL spin-off, is founded on pioneered research over the past decade that identifies the crucial roles of two proteins, Trio and Complexin, in preserving motor function. To our knowledge, we are the first to show that reactivating these mechanisms can greatly mitigate mobility loss associated with aging. These scientific discoveries have been highlighted in multiple outlets, including The Scientist magazine.

Juvion is transforming these groundbreaking scientific discoveries into next-generation therapeutic solutions derived from natural resources to support healthier aging. These solutions aim to be accessible to individuals across various age groups, helping to preserve motor function over a longer period as they age. The development of these compounds is supported by a cutting-edge proprietary in vivo platform that integrates AI, robotics, and machine learning, enabling a sustainable, faster, and more cost-effective approach using Drosophila as a primary predictive animal model. JUV-083, one of Juvion’s leading candidates, is currently undergoing validation in mouse models and is on track to advance to human testing.

With a profound understanding of age-related motor function decline and the development of its innovative platform, Juvion is well-positioned to deliver cutting-edge solutions to the rapidly expanding health and wellness market. By promoting healthier aging and delaying conditions like sarcopenia, Juvion aims to narrow the gap between life span and healthspan for millions of people.

Go-to-Market Strategy /Traction/Business plan:

With the rapidly growing aging population, the market for anti-aging products is expanding at an unprecedented rate. Additionally, the global dietary supplement market is projected to reach $221 billion by 2030, with an expected CAGR of 6.5% from 2024 to 2030. According to McKinsey Health Institute, extending healthspan by just one year could create an astonishing $38 trillion in societal value in the U.S. alone. To align with this rapidly growing market, Juvion has two product portfolios as part of its addressable market strategy.

Juvion Therapeutic Solutions: Juvion's product will be the first scientifically backed preventative solution to address age-related mobility decline and delay sarcopenia by maintaining neuron-muscle connectivity as aging progresses. The product is expected to be market-ready by 2027, following successful six-month clinical evidence tests in humans. Distribution will follow a B2B strategy, and we are already in discussions with DSM-Firmenich, Mitsubishi Life Sciences (Japan), and Cipla (India) to establish global partnerships.

Juvion Platform: Juvion’s proprietary platform is set to begin generating revenue starting in 2025. The platform is designed to test compounds for efficacy in improving motor function and mobility, supporting scientific licensing agreements. An agreement has already been signed with DSM-firmenich to test their compounds, and active discussions are ongoing with Nestlé for similar collaborations.

IP:

In 2022, the discovery of the Trio protein's role in maintaining neuron-muscle connectivity was submitted for IP protection through EPFL's TTO office. Potential leads, including JUV-083, are being finalized for IP protection, which also covers compound combinations to enhance effectiveness under the same framework. Furthermore, new technology within the Juvion platform is being prepared for future patent applications. Securing IP for both Juvion's products and platform will provide a crucial competitive edge, safeguarding proprietary formulations as we progress toward product development and market launch.